Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

NCT01533246 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

17

Enrollment

NIH

Sponsor class

Conditions

Adenocarcinoma of the Prostate
Hormone-resistant Prostate Cancer
Recurrent Prostate Cancer
Stage IV Prostate Cancer

Interventions

DRUG: linsitinib
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)